Biofrontera (BFRI) vs Dare Bioscience (DARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Dare Bioscience (DARE) over the past year, losing 9.0% versus a loss of 66.3%. Dare Bioscience is the larger company by market cap ($15.2 million vs $14.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | DARE |
|---|---|---|
| Share price | $0.9801 | $0.7704 |
| Market cap | $14.56M | $15.15M |
| 1-day change | +6.67% | -0.23% |
| YTD return | +61.19% | -59.99% |
| 1-year return | -9.03% | -66.28% |
| 5-year return | — | -95.90% |
| Forward P/E | 2.28 | — |
| EPS (TTM) | $-0.43 | $-0.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $3.78 |
| 52-week low | $0.555 | $0.69 |
| Distance from 52-week high | -40.96% | -79.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +512.18% | +981.26% |
| Average volume | 547.45K | 525.06K |
| Shares outstanding | 14.85M | 19.67M |
| Employees | 84 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed DARE by 57.2 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Dare Bioscience
DARE stock →Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
BFRI vs DARE FAQ
Which is bigger, Biofrontera or Dare Bioscience?
Dare Bioscience (DARE) is larger, with a market capitalization of $15.15M compared with $14.56M for Biofrontera (BFRI).
Which stock has performed better over the past year, BFRI or DARE?
BFRI returned -9.03% over the past 12 months, compared with -66.28% for DARE (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Dare Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.